옵션 체인은 다양한 행사가격과 만기일에 대한 Credo Technology Group의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Credo Technology Group에 대한 시장 심리를 평가합니다..

Credo Technology Group (NASDAQ:CRDO) 주식, 옵션 체인

Credo Technology Group

Credo Technology Group Holding Ltd delivers high-speed solutions to break bandwidth barriers on every wired connection in the data infrastructure market. It provides secure, high-speed connectivity solutions that deliver improved power and cost efficiency as data rates and corresponding bandwidth requirements increase exponentially throughout the data infrastructure market. It has a geographic presence in Hong Kong, the United States, Mainland China, Taiwan, and the Rest of the World.

acciones sobrevendidas, acciones en tendencia

Equities

News

Markets

$BTC

CRDO

CRWD

MSTR

TSLA

화요일(4일) 미국 증시는 도널드 트럼프 대통령의 주요 무역 파트너에 대한 관세가 발효되면서 글로벌 무역 긴장이 심화됨에 따라 하락했다. 다우존스 산업평균지수는 1.55% 하락한 42,520.99포인트, S&amp;P 500 지수는 1.22% 하락한 5,778.15포인트를 기록했다. 나스닥 종합지수는 0.35% 하락한 18,285.16포인트로 조정 영역에 근접했다.

화요일 주목받은 주식: 스트레티지, 크라우드스트라이크, 베스트바이, 크레도 및 테슬라

Super Micro Computer, Inc. SMCI

Large Cap

Movers

Trading Ideas

DOCU

LULU

MRVL

PSTG

RBRK

ROKU

SMCI

이들 11개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 크레도 테크놀로지 그룹 홀딩(NASDAQ:CRDO) 주식은 2분기 실적 발표 후 주가가 51.61% 급등하였으며, 여러 회사들이 주식에 대한 가격 예측을 상향 조정했다.

슈퍼 마이크로, 룰루레몬 및 로쿠 지난주 최고 성과를 보여준 11개 대형주 중 일부 (12월 2일-6일)

Credo Technology Group Holding Ltd

크레도 테크놀로지 그룹 홀딩스(NASDAQ:CRDO)의 주가는 월요일에 예상치를 크게 상회하는 2025회계연도 2분기 재무 실적을 발표한 후 화요일(3일) 급등하고 있다. 알아 두어야 할 내용은 다음과 같다.

크레도 테크놀로지 주가 48% 급등, 무슨 일일까?

Credo Technology Group Holding Ltd - Ordinary Shares

Cerrado Gold Inc

<ul>
<li>Reflects business philosophy of commercial success through patient accessibility</li>
<li>Recently executed agreement with CD 8 Technology Services LLC providing up to $50 million for Company's dedicated R&amp;D and manufacturing facility; no impact on shareholder equity</li>
</ul>
WARREN, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=jSbvQBvaGIm4QLP6v08YeTss46FD6iNPmKu1voOrF5vXBpzNT7keXDuzL599zfMXevkmSVtVucFZru53B0ZvFw==">Tevogen</a> ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>), reaffirms its top-line revenue forecast for its oncology pipeline, projecting $1 billion in revenue in its launch year and a cumulative 5-year estimate of between $10 billion and $14 billion. The forecast reflects the company's unique, faster, and cost-efficient drug development model which has the potential to serve as a blueprint to ensure sustainable medical innovation for years to come.

Guidance

TVGN

Tevogen Reaffirms Its Top-Line Revenue Forecast For Its Oncology Pipeline, Projecting $1B In Revenue In Its Launch Year And A Cumulative 5-Year Estimate Of Between $10B-$14B

Earnings

Earnings Beats

ALRS

Alerus Finl Q1 Adj. EPS $0.52 Beats $0.42 Estimate, Sales $68.83M Beat $66.16M Estimate

Biotech

General

ARTV

Artiva Biotherapeutics to Reveal Longer-term Phase 1/2 Data For AlloNK in Combination With Rituximab In Patients With B-cell-Non-Hodgkin Lymphoma At the ASGCT 28th Annual Meeting

COPT Defense Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CDP#NYSE">CDP</a>) narrows FY2025 FFO guidance from $2.62-$2.70 to $2.63-$2.69 vs $2.66 analyst estimate..

COPT Defense Props Narrows FY2025 FFO Guidance from $2.62-$2.70 to $2.63-$2.69 vs $2.66 Est

COPT Defense Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CDP#NYSE">CDP</a>) is looking for Q2 FFO of $0.65-$0.67 vs $0.67 analyst estimate..

COPT Defense Props Sees Q2 FFO $0.65-$0.67 vs $0.67 Est

COPT Defense (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CDP#NYSE">CDP</a>) reported quarterly earnings of $0.65 per share which met the analyst consensus estimate. This is a 4.84 percent increase over earnings of $0.62 per share from the same period last year. The company reported quarterly sales of $187.86 million which beat the analyst consensus estimate of $175.86 million by 6.82 percent. This is a 2.80 percent decrease over sales of $193.27 million the same period last year.

COPT Defense Q1 FFO $0.65, Inline, Sales $187.86M Beat $175.86M Estimate

Nucor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) reported quarterly earnings of $0.77 per share which beat the analyst consensus estimate of $0.64 by 20.31 percent. This is a 77.75 percent decrease over earnings of $3.46 per share from the same period last year. The company reported quarterly sales of $7.83 billion which beat the analyst consensus estimate of $7.23 billion by 8.29 percent. This is a 3.77 percent decrease over sales of $8.14 billion the same period last year.

Nucor Q1 Adj. EPS $0.77 Beats $0.64 Estimate, Sales $7.83B Beat $7.23B Estimate

ITeos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITOS#NASDAQ">ITOS</a>) reported quarterly losses of $(0.80) per share which beat the analyst consensus estimate of $(0.95) by 15.79 percent. This is a 25.23 percent increase over losses of $(1.07) per share from the same period last year.

ITOS

ITeos Therapeutics Q1 EPS $(0.80) Beats $(0.95) Estimate

ACET

Adicet Bio To Give Oral Presentation For Its Preclinical ADI-270 Data At The American Society Of Gene And Cell Therapy 28th Annual Meeting

Bitcoin (<a href="https://www.benzinga.com/quote/BTC-USD">BTC</a>) might not be digital gold due to its risky nature. But as an investment over the last 12 months, it's up 49% while the SPDR Gold Trust (<a href="https://www.benzinga.com/quote/GLD">GLD</a>) ETF is up 43%. Nasdaq is up around 8%. Looked at in that time frame, BTC is as good as gold, for real.
"While bitcoin continues to function as an ultra risk-on asset, paradoxically, the digital gold narrative has continued to gather strength," said Greg Waisman, Chief Operating Officer at Mercuryo, a fintech company headquartered in Canada.&nbsp;
"Bitcoin has displayed relative resilience against tariff concerns and a potential recession," he said, noting that BTC has outperformed tech stocks all year. "That might make Bitcoin seen by some as displaying characteristics more akin to a store of value such as gold," Waisman said.
The notion that Bitcoin was "as good as gold" began around 2021. Michael Novogratz, founding CEO of Galaxy Digital Holdings (<a href="https://www.benzinga.com/quote/BRPHF">BRPHF</a>), a crypto investment firm that trades on the Toronto Stock Exchange, <a href="https://www.goldmansachs.com/pdfs/insights/pages/crypto-a-new-asset-class-f/report.pdf?utm">said</a> at the time that "Bitcoin is a really convenient way to store value. The main reason everyone got into bitcoin is the same reason they got into gold—the current macro backdrop is tailor-made for it."
Novogratz later called it <a href="https://www.goldmansachs.com/insights/articles/from_briefings_18-feb-2021?utm">"digital gold"</a> during a Goldman Sachs event that same year. That theme has stuck around ever since.&nbsp;
"The digital gold label reflects Bitcoin's core proposition: scarcity, decentralization, and its role as a store of value," said Mithil Thakore, Co-Founder &amp; CEO at <a href="https://www.benzinga.com/quote/VELAR-USD">Velar</a>, a Dubai-based DeFi play.
If Bitcoin is to be likened as digital gold for its store of value, then it must be seen as the more rambunctious cousin to the yellow metal. Looked at over the last year and Bitcoin looks exactly like gold when compared to GLD. Looked at over five years and Bitcoin is a runaway train, far outpacing everything in the market, with the possible exception of Nvidia (<a href="https://www.benzinga.com/quote/NVDA">NVDA</a>) stocks. Over the last three months, Bitcoin is down 10.7%, but that's better than the Nasdaq. And it has also held its value more than Nvidia.
Gold Safer Bitcoin Since Trump, But Bitcoin Safer Bet Than The S&amp;P 500
Despite Bitcoin being beaten by gold during the recent volatility, it's done better than the S&amp;P 500. Investors lost more money holding the SPDR S&amp;P 500 (<a href="https://www.benzinga.com/quote/SPY">SPY</a>) than they lost in BTC.
In official circles, of course, Bitcoin is not digital gold. The Securities and Exchange Commission <a href="https://www.sec.gov/comments/sr-cboebzx-2021-019/srcboebzx2021019-8857582-239811.pdf?utm">makes it clear</a> to investors: don't get your wires crossed on this trade.&nbsp;
Unlike gold, Bitcoin is not a collateral currency. Central banks hold gold because it can be a ready source of foreign exchange, especially for dollars. Gold can also serve as a collateral to access dollars during a crisis. That's why gold has value because of its repeated historical pattern acting as insurance to access liquidity during times of extreme crisis. As of now, Bitcoin has yet to demonstrate the role as a collateral currency, let alone for central banks.
Earlier this month, Peter Schiff panned the idea of Bitcoin as a safe haven investment. He was mostly criticizing the Trump administration's plan to consider holding BTC in a strategic reserve fund.
"I mean, if it's digital gold, it should have something in common with gold. It should trade similarly to Gold. It should have some kind of positive correlation. It doesn't have any," Schiff <a href="https://www.benzinga.com/25/04/44580634/bitcoin-is-digital-risk-not-digital-gold-asserts-peter-schiff">said</a> during his YouTube podcast. He called it the "anti-gold."&nbsp;
"Bitcoin is more than just a passive hedge," said Thakore. "Unlike gold, which sits in vaults, Bitcoin is programmable and forms the backbone of a new financial system." At Velar, Thakore said he is saying a shift from passive holding of Bitcoin in digital wallets, to active utility as a currency.&nbsp;
"Yes, Bitcoin is way more volatile than gold will ever be, but that volatility also reflects its growth phase," Thakore said. Gold has been around for thousands of years.&nbsp; Bitcoin was created in 2009. "We're witnessing the monetization of the number one digital asset in real time," he said.&nbsp; "In that sense, Bitcoin is gold with a built-in accelerator."
Disclosure: The writer of this article is a Bitcoin investor.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Commodities

Opinion

Bitcoin Might Not Be As Good As Gold Yet, But This Year, It Sure Is Acting Like It

Cellectis (the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLLS#NASDAQ">CLLS</a>), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today unveils research data on TALEN&#xAE;-mediated non-viral transgene insertion for advancing cellular and gene therapies, and advancements in genetic editing using TALE base editors (TALEB), at the Society of Gene and Cell Therapy (ASGCT) annual meeting, that will be held on May 13-17, 2025 in New Orleans.

CLLS

Cellectis Presents Research Data On TALEN And TALEB Technologies For Gene And Cellular Therapies At ASGCT Annual Meeting

Fractyl Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GUTS#NASDAQ">GUTS</a>) ("the Company"), a metabolic therapeutics company focused on pattern-breaking approaches to treat the root causes of obesity and type 2 diabetes (T2D), today announced that it will deliver an oral presentation of compelling preclinical data from its Rejuva single-administration Smart GLP-1 pancreatic gene therapy platform at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting, taking place May 13-17, 2025, in New Orleans, Louisiana.
Oral Presentation Details:
Title: Endoscopic Ultrasound-Guided Delivery of Human Glucagon-like Peptide-1 Pancreatic Gene Therapy: Safety and Feasibility in a Porcine Model Session: AAV Preclinical and Proof-of-Concept Studies Date and Time: Saturday, May 17, 2025, 9:15 a.m. – 9:30 a.m. CT Location: NOLA Theater A
The presentation will be available via the <a href="https://www.globenewswire.com/Tracker?data=aacUCQgF_Oqe0d8e_y3hmsG1Yc1wJ8J7vtDGrOFywijpE8bvkVPkvuBFk2XlW5vg7tSmk1RCOaeYE2GPEfH0QP9VxkDuoOvEvNpyCBVlpXesQo6kwqP-UmcEIaAmBw0khOcq05KG28BH3sebErxYrKb8bPbMDb5NILxzEUHB5dc=">Presentations &amp; Publications</a> section of the Fractyl website once it concludes on May 17, 2025. &nbsp;

GUTS

Fractyl Health Announces It Will Present Preclinical Data From Its Rejuva Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform At American Society Of Gene And Cell Therapy 2025 Annual Meeting May 13-17, 2025, In New Orleans, Louisiana.

Beyond, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYON#NYSE">BYON</a>) released its first-quarter results after Monday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/25/04/b45051710/beyond-inc-delivers-significant-financial-improvement-across-key-operational-guideposts-signals-im">details from the report.&nbsp;</a>
The Details:&nbsp;Beyond reported quarterly losses of&nbsp;42 cents per share, which beat the analyst consensus estimate of&nbsp;losses of 54 cents. Quarterly revenue came in at $231.75 million,&nbsp;which missed the analyst consensus estimate of&nbsp;$288.15 million&nbsp;and is a&nbsp;decrease from revenue of&nbsp;$382.28 million&nbsp;from the same period last year.
Read Next: <a href="https://www.benzinga.com/news/global/25/04/44952117/apple-and-meta-fined-nearly-800-million-for-violating-european-unions-digital-markets-act?utm_source=articleShare">Apple And Meta Fined Nearly $800 Million For Violating European Union&#8217;s Digital Markets Act</a>&nbsp;
For the first quarter, Beyond reported: 
<ul>
<li>Gross profit of $58 million, or 25.1% of net revenue, a 560 bps improvement year-over-year. </li>
<li>Sales &amp; Marketing expense of $31 million, or 13.5% of net revenue, a 430 bps improvement year-over-year. </li>
<li>Technology and G&amp;A expense of $41 million vs $50 million in 2024, a $9 million improvement year-over-year. </li>
</ul>
&#8220;While the previously disclosed decision to eliminate non-contributory SKUs and vendors led to lower revenue, we are steadfast in building a more stable foundation for profitability and growth. The sequential improvements we&#8217;ve seen —particularly in gross margin expansion and fixed cost reductions — underscore the intensity I expect in restoring the financial discipline critical to building a profitable growing business,&#8221; said Adrianne Lee, CFO of Beyond.
Outlook:&nbsp;The company said it believes it is 60 days out from transitioning from restructuring to revenue growth. 
BYON Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Beyond stock was up 22.01% after-hours at $5.03 at publication on Monday.  
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44956197/amazon-price-target-slashed-again-on-wild-card-tariff-concerns?utm_source=articleShare">Amazon Price Target Slashed Again On &#8216;Wild Card&#8217; Tariff Concerns&nbsp;</a></li>
</ul>
Photo: Shutterstock

After-Hours Center

Tech

BYON

Beyond Stock Rallies After Q1 EPS Beat Estimates: Details

Events

SGMO

Sangamo Therapeutics To Present At 28th Annual Meeting of the American Society of Gene & Cell Therapy May 13-17

ORIC

ORIC® Pharmaceuticals Presents Poster At AACR Highlighting Data On ORIC-944

SAIH

Saiheat FY EPS $(3.4582) Up From $(3.7916) YoY, Sales $5.54M Down From $6.78M YoY

Universal Health Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) reported quarterly earnings of $4.84 per share which beat the analyst consensus estimate of $4.35 by 11.26 percent. This is a 30.81 percent increase over earnings of $3.70 per share from the same period last year. The company reported quarterly sales of $4.10 billion which missed the analyst consensus estimate of $4.15 billion by 1.31 percent. This is a 6.63 percent increase over sales of $3.85 billion the same period last year.

Earnings Misses

Universal Health Servs Q1 Adj. EPS $4.84 Beats $4.35 Estimate, Sales $4.10B Miss $4.15B Estimate

EDIT

Editas Medicine Announces Five Abstracts At 28th Annual Meeting Of American Society Of Gene And Cell Therapy

Preclinical data to showcase the potential of regRNA-targeting to increase protein levels in a clinically meaningful way by upregulating gene expression
Interim safety data including patient demographic data from all SAD cohorts of the first-in-human Phase 1 clinical trial of CMP-CPS-001 in healthy volunteers to be presented
CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMP#NASDAQ">CAMP</a>), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced three oral presentations at the upcoming 28th Annual Meeting of the American Society of Gene and Cell Therapy, taking place in New Orleans, LA, May 13 – 17, 2025.
Details for the oral presentations are as follows:
Title: Targeting Regulatory RNAs with Antisense Oligonucleotides for the Potential Treatment of Urea Cycle Disorders Presenter: Dan Tardiff, Ph.D. Session title: Oligonucleotide Therapeutics II Session date and time: Friday May 16, 2025, 3:45 PM - 5:40 PM CT
Title: Targeting Regulatory RNAs with Antisense Oligonucleotides for the Potential Treatment of SYNGAP1-Related Disorders Presenter: Dan Tardiff, Ph.D. Session title: Oligonucleotide Therapeutics II Session date and time: May 16, 2025, 3:45 PM - 5:40 PM CT
Title: A First-in-Human Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study (SAD, MAD) in Healthy Volunteers to Evaluate the Safety and Tolerability of an Investigational Antisense Oligonucleotide Therapy (CMP-CPS-001) for the Treatment of Urea&nbsp;Cycle Diseases (UCDs): Interim Safety Readout Presenter: Yuri Maricich, M.D. Session title: Oligonucleotide Therapeutics II Session date and time: May 16, 2025, 3:45 PM - 5:40 PM CT

CAMP

CAMP4 Announces It Will Present New Preclinical Data From Its Urea Cycle Disorders And SYNGAP1-Related Disorders Programs At 28th American Society Of Gene And Cell Therapy Annual Meeting May13-17, 2025 In New Orleans, Lousiana

RBB Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBB#NASDAQ">RBB</a>) reported quarterly earnings of $0.13 per share which missed the analyst consensus estimate of $0.38 by 65.79 percent. This is a 69.77 percent decrease over earnings of $0.43 per share from the same period last year.

RBB Bancorp Q1 EPS $0.13 Misses $0.38 Estimate

Press Releases

Credo Schedules Third Quarter Fiscal Year 2025 Financial Results Conference Call

Credo's PCIe® Retimer Successfully Passes PCI-SIG® Compliance

Credo Reports Third Quarter of Fiscal Year 2025 Financial Results

Credo Showcasing AEC PCIe Products for AI Scaling at NVIDIA GTC 2025

Credo Files AEC Patent Infringement Complaint Against Amphenol, Molex, TE Connectivity, and Volex with United States International Trade Commission

Credo and XConn to Showcase Seamless GPU Cluster at NVIDIA GTC

WPG Americas Accelerates High-Speed Connectivity Solutions through Credo Partnership

Credo to Showcase AI Scale Out Fabric Featuring Credo Optical DSPs at OFC 2025

Credo Named a Winner of the 2025 Top Workplaces USA Award

Credo Unveils the Lark Family - Setting a New Benchmark for Low-Power 800G Optical DSPs

Analog Devices

Astera Labs

Advanced Micro Devices, Inc. - Common Stock

Advanced Micro Devices

Arm Holdings plc - American Depositary Shares

ARM Holdings

ASE Technology Holding Co., Ltd. American Depositary Shares (each representing Two Common Shares)

Comments

Credo Technology Group

Credo Technology Group (CRDO) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌